Nykode Therapeutics to Present Interim Data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026

19 Dec 2025 14:45 CET

Oslo, Norway, December 19, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced the oral presentation of
interim data from the VB-C-03 trial at the 10th International Congress on
Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026.

The VB-C-03 trial is investigating abi-suva in combination with KEYTRUDA®
(pembrolizumab) in 1st line unresectable recurrent or metastatic head and neck
cancer patients (NCT06016920). Nykode is further advancing abi-suva development
in 1st line head and neck cancer through the Abili-T phase 2 randomized
controlled trial.

Presentation details:
Location: ICHNO 2026, Seville, Spain
Date: March 20, 2026
Time: 15:15-16:15 (CET)

The abstract is expected to be published on February 19, 2026.

Michael Engsig, Chief Executive Officer of Nykode, commented: “As previously
announced, we look forward to providing further insight into the C-03 clinical
data from 1st line head and neck cancer patients which supported our recently
communicated strategy to further investigate abi-suva in this population with
significant unmet needs.”

Furthermore, Michael Engsig, CEO and Agnete Fredriksen, CSO and Co-founder of
Nykode Therapeutics will also be attending the 44th Annual J.P. Morgan
Healthcare Conference and are available for 1:1 meetings.


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode’s modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are abi-suva, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of late-line r/m
cervical cancer. Abi-suva is currently being further developed in head and neck
cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been
investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

More information:
Access the news on Oslo Bors NewsWeb site

662566_251219_ICHNO conference.pdf